

Di seguito la documentazione e un'articolata bibliografia sull'offerta della vaccinazione antipneumococcica in età pediatrica in Piemonte

1. Prevenar13: riassunto caratteristiche di prodotto  
([https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer\\_001533\\_039550\\_RCP.pdf&retry=0&sys=mob113](https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_001533_039550_RCP.pdf&retry=0&sys=mob113))
2. Synflorix: riassunto delle caratteristiche di prodotto  
([https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer\\_000231\\_039104\\_RCP.pdf&retry=0&sys=mob113](https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000231_039104_RCP.pdf&retry=0&sys=mob113))
3. Regione Piemonte. La vaccinazione dei soggetti che presentano un rischio aumentato di infezione invasiva da batteri capsulati (*S. pneumoniae*, *N. meningitidis*, *H. influenzae*). Aprile 2017  
([https://www.seremi.it/sites/default/files/Protocollo%20MIB\\_2017.pdf](https://www.seremi.it/sites/default/files/Protocollo%20MIB_2017.pdf))
4. Vaccini anti-pneumococcici Prevenar 13 e Synflorix. Ministero della Salute. Protocollo n. 0019468-23/06/2017-DGPRES-DGPRES-P
5. Systematic Review on "Pneumococcal Conjugate Vaccine (PCV) Product Assessment" condotta da ricercatori affiliati al Vaccine Access Center, US Center for Disease Control, University College of London, Agency de Medicine Preventive and WHO. (<https://www.jhsph.edu/research/centers-and-institutes/ivac/resources/pcv-product-assessment-april-25-2017.pdf>)
6. World Health Organization (WHO). Weekly epidemiological record. Pneumococcal conjugate vaccines. 2017, December 1; vol 92, 48 (pp 729-748) (<http://www.who.int/wer/2017/wer9248/en/>)
7. Cavallo R. Promesse mantenute (o da mantenere?). Quaderni ACP 2018, 1. ([https://www.acp.it/wp-content/uploads/Quaderni-acp-2018\\_251\\_42-43.pdf](https://www.acp.it/wp-content/uploads/Quaderni-acp-2018_251_42-43.pdf))
8. Ladhani SN et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018 Jan 26: S1473-3099(18)30052-5
9. Le malattie batteriche invasive in Piemonte. Anno 2016  
<https://www.seremi.it/sites/default/files/Report%20MIB%202016%20ed.%202017.pdf>